Immuneering Yönetim

Yönetim kriter kontrolleri 3/4

Immuneering CEO'su Ben Zeskind, Feb2008 tarihinde atandı, in görev süresi 16.92 yıldır. in toplam yıllık tazminatı $ 1.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 30.9% maaş ve 69.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 10.23% ine doğrudan sahiptir ve bu hisseler $ 7.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.3 yıldır.

Anahtar bilgiler

Ben Zeskind

İcra Kurulu Başkanı

US$1.9m

Toplam tazminat

CEO maaş yüzdesi	30.9%
CEO görev süresi	16.9yrs
CEO sahipliği	10.2%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ben Zeskind'un ücretlendirmesi Immuneering'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$58m
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$2m	US$593k	-US$53m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$570k	-US$51m
Sep 30 2022	n/a	n/a	-US$48m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$2m	US$400k	-US$34m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$806k	US$293k	-US$17m

Tazminat ve Piyasa: Ben 'nin toplam tazminatı ($USD 1.92M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 642.68K ).

Tazminat ve Kazançlar: Ben 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ben Zeskind (42 yo)

16.9yrs

Görev süresi

US$1,918,201

Tazminat

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Benjamin Zeskind	Co-Founder	16.9yrs	US$1.92m	10.23% $ 7.4m
Robert Carpenter	Co-Founder & Chair Emeritus	17yrs	US$202.74k	3.7% $ 2.7m
Brett Hall	Chief Scientific Officer	5.2yrs	US$1.40m	1.11% $ 809.4k
Harold Brakewood	Chief Business Officer	1.8yrs	US$1.57m	0.013% $ 9.1k
Mallory Morales	Principal Financial & Accounting Officer	2.4yrs	Veri yok	0.041% $ 29.8k
Paula George	Director of Accounting & Operations and Assistant Corporate Controller	3.3yrs	Veri yok	Veri yok
Michael Bookman	Chief Legal Officer & Secretary	3.5yrs	Veri yok	0.012% $ 9.0k
Leah Neufeld	Chief People Officer	2.3yrs	Veri yok	0.032% $ 23.5k
Peter King	Head of Discovery & VP	no data	Veri yok	Veri yok
Praveen Nair	Head of Translational Pharmacology & VP	2.8yrs	Veri yok	Veri yok
Stephen Sebastian	Executive Director & Corporate Controller	3.3yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: IMRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Benjamin Zeskind	Co-Founder	16.9yrs	US$1.92m	10.23% $ 7.4m
Robert Carpenter	Co-Founder & Chair Emeritus	15.7yrs	US$202.74k	3.7% $ 2.7m
Laurie Keating	Independent Director	3.8yrs	US$179.88k	0.045% $ 32.8k
Douglas Lauffenburger	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Thomas Schall	Director	less than a year	Veri yok	0.0093% $ 6.8k
Peter Feinberg	Director	4yrs	US$165.67k	3.53% $ 2.6m
Jordan Berlin	Member of Pancreatic Cancer Advisory Board	less than a year	Veri yok	Veri yok
Ann Berman	Independent Chair	3.5yrs	US$181.38k	0.22% $ 157.9k
Diana Hausman	Independent Director	3yrs	US$175.38k	0% $ 0
Tanios Bekaii-Saab	Member of Pancreatic Cancer Advisory Board	no data	Veri yok	Veri yok
Vincent Chung	Member of Pancreatic Cancer Advisory Board	less than a year	Veri yok	Veri yok
Shubham Pant	Member of Pancreatic Cancer Advisory Board	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/06 22:00
Gün Sonu Hisse Fiyatı	2025/01/03 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Immuneering Corporation 12 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yevgeniya Livshits	Chardan Capital Markets, LLC
Michael Schmidt	Guggenheim Securities, LLC
Michael Yee	Jefferies LLC

Immuneering Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Independent Chair recently bought US$123k worth of stock

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

Recent updates

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri